Novartis Ag (NVS) Return on Capital Employed (2009 - 2010)
Novartis Ag recorded quarterly Return on Capital Employed of 0.0% in Q1 2010, down 100.0% quarter-over-quarter from 22.67% in Q4 2009, and down 2977.0% year-over-year from 0.0% in Q1 2009.
Novartis Ag's Return on Capital Employed history runs 2 years deep, the most recent figure standing at 0.0% for Q1 2010.
- In Q1 2010, Return on Capital Employed fell 2977.0% year-over-year to 0.0%; the TTM figure through Mar 2010 stood at 0.0% (down 2977.0% YoY), while the FY2025 annual figure was 22.24%, up 216.0% from the prior year.
- Return on Capital Employed came in at 0.0% for Q1 2010 at Novartis Ag, down from 22.67% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 29.77% in Q1 2009 to a low of 0.0% in Q1 2010.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 42.94% |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 28.18% |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 16.47% |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | -5.22% |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 15.87% |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 21.53% |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | -10.20% |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | -6.84% |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2010 | 0.00% |
| Dec 31, 2009 | 22.67% |
| Sep 30, 2009 | 7.55% |
| Jun 30, 2009 | 7.53% |
| Mar 31, 2009 | 29.77% |